The successful candidate will break news on an industry that has benefited tremendously, both in terms of profit and influence, from developing vaccines and treatments critical to alleviating the COVID pandemic. At the same time, the industry is fending off efforts to curb the rising costs of prescription medicines and faces increasing pushback from national regulators over drug approvals.
This reporter would break news on how companies like Pfizer and Moderna will spend the billions of dollars earned off the pandemic, including a new push for acquisitions after a long hiatus. The candidate will report on how the pharma industry is exercising its enhanced leverage with governments, in Washington and abroad, seeking to sway major policy decisions on how drugs are approved and priced, from insulin to Alzheimer’s treatments.
The reporter would be deeply sourced among pharmaceutical and biotech executives, U.S. government health officials and industry investors. The preferred location for the role is New York.
About the Role
As our U.S. Pharmaceutical Industry Reporter, you will:
About You
To be our U.S. Pharmaceutical Industry Reporter, you will likely have:
(Internal candidates: Please note this position is incorrectly listed as being in the EIC job family).
Please note, the deadline for applications is Sunday 5th June 2022.
To apply, go here.
CNBC senior vice president Dan Colarusso sent out the following on Monday: Before this year comes to…
Business Insider editor in chief Jamie Heller sent out the following on Monday: I'm excited to share…
Former CoinDesk editorial staffer Michael McSweeney writes about the recent happenings at the cryptocurrency news site, where…
Manas Pratap Singh, finance editor for LinkedIn News Europe, has left for a new opportunity…
Washington Post executive editor Matt Murray sent out the following on Friday: Dear All, Over the last…
The Financial Times has hired Barbara Moens to cover competition and tech in Brussels. She will start…